SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0000899243-22-034545
Filing Date
2022-10-31
Accepted
2022-10-31 16:05:15
Documents
3
Period of Report
2022-10-21

Document Format Files

Seq Description Document Type Size
1 FORM 3 SUBMISSION doc3.html 3  
1 FORM 3 SUBMISSION doc3.xml 3 3929
2 EX-24.1 DOCUMENT attachment1.htm EX-24.1 3800
3 EX-24.2 DOCUMENT attachment2.htm EX-24.2 3786
  Complete submission text file 0000899243-22-034545.txt   13732
Mailing Address 2-5-1, NIHONBASHI-HONCHO CHUO-KU TOKYO M0 103-8411
Business Address 2-5-1, NIHONBASHI-HONCHO CHUO-KU TOKYO M0 103-8411 81-3-3244-3231
Astellas Pharma Inc. (Reporting) CIK: 0001376684 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-39536 | Film No.: 221345990

Mailing Address 600 CALIFORNIA ST., 17TH FLOOR SAN FRANCISCO CA 94108
Business Address 600 CALIFORNIA ST., 17TH FLOOR SAN FRANCISCO CA 94108 415-638-6556
Audentes Therapeutics, Inc. (Reporting) CIK: 0001628738 (see all company filings)

State of Incorp.: DE | Fiscal Year End: 1231
Type: 3 | Act: 34 | File No.: 001-39536 | Film No.: 221345991
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247
Business Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247 (214) 612-0000
Taysha Gene Therapies, Inc. (Issuer) CIK: 0001806310 (see all company filings)

IRS No.: 843199512 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)